GT BIOPHARMA, INC. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
GT BIOPHARMA, INC. (GTBP) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of -$89.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-08-14
- GT BIOPHARMA, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$197.00K.
- GT BIOPHARMA, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $108.00K.
- GT BIOPHARMA, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $1.14M, a 2.65% decline year-over-year.
- GT BIOPHARMA, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$813.00K, a 181.46% decline year-over-year.
- GT BIOPHARMA, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was -$1.30M, a 238.42% decline from fiscal 2024.
- GT BIOPHARMA, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2024 was $937.00K, a 52.24% decline from fiscal 2023.
- GT BIOPHARMA, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2023 was $1.96M.
- GT BIOPHARMA, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2022 was -$2.03M, a 128.68% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$197.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$89.00K 10-Q · filed 2026-08-14 | $1.05M derived: sum of 3 quarters · filed 2026-08-14 | $237.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $108.00K 10-Q · filed 2026-05-15 | $1.25M derived: sum of 2 quarters · filed 2026-05-15 | $434.00K derived: sum of 3 quarters · filed 2026-05-15 | $102.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $1.14M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | $326.00K derived: sum of 2 quarters · filed 2026-03-06 | -$6.00K derived: sum of 3 quarters · filed 2026-08-14 | -$1.30M 10-K · filed 2026-03-02 | |
| 2025-09-30 | -$813.00K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2026-03-06 | -$1.15M derived: sum of 2 quarters · filed 2026-08-14 | -$2.44M 10-Q/A · filed 2026-03-06 | -$1.27M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | -$332.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.62M 10-Q · filed 2026-08-14 | -$453.00K derived: sum of 3 quarters · filed 2026-08-14 | $545.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | -$1.29M 10-Q · filed 2026-05-15 | -$121.00K derived: sum of 2 quarters · filed 2026-05-15 | $877.00K derived: sum of 3 quarters · filed 2026-05-15 | $993.00K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $1.17M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | $2.17M derived: sum of 2 quarters · filed 2026-03-06 | $2.28M derived: sum of 3 quarters · filed 2026-03-06 | $937.00K 10-K · filed 2026-03-02 | |
| 2024-09-30 | $998.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2026-03-06 | $1.11M derived: sum of 2 quarters · filed 2026-03-06 | -$233.00K 10-Q/A · filed 2026-03-06 | $292.00K derived: sum of 4 quarters · filed 2026-03-06 | |
| 2024-06-30 | $116.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2026-03-06 | -$1.23M 10-Q/A · filed 2026-03-06 | -$706.00K derived: sum of 3 quarters · filed 2026-03-06 | -$321.00K derived: sum of 4 quarters · filed 2026-03-06 | |
| 2024-03-31 | -$1.35M 10-Q · filed 2025-05-15 | -$822.00K derived: sum of 2 quarters · filed 2025-05-15 | -$437.00K derived: sum of 3 quarters · filed 2025-05-15 | $644.00K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $525.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $910.00K derived: sum of 2 quarters · filed 2025-02-21 | $1.99M derived: sum of 3 quarters · filed 2025-02-21 | $1.96M 10-K · filed 2025-02-21 | |
| 2023-09-30 | $385.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.47M derived: sum of 2 quarters · filed 2024-11-14 | $1.44M 10-Q · filed 2024-11-14 | $4.67M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.05M 10-Q · filed 2024-08-14 | $4.28M derived: sum of 3 quarters · filed 2024-08-14 | $751.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$29.00K 10-Q · filed 2024-05-15 | $3.20M derived: sum of 2 quarters · filed 2024-05-15 | -$330.00K derived: sum of 3 quarters · filed 2024-05-15 | -$1.22M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $3.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$301.00K derived: sum of 2 quarters · filed 2024-03-26 | -$1.19M derived: sum of 3 quarters · filed 2024-03-26 | -$2.03M 10-K · filed 2024-03-26 | |
| 2022-09-30 | -$3.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$4.42M derived: sum of 2 quarters · filed 2023-11-01 | -$5.26M 10-Q · filed 2023-11-01 | -$2.01M 10-Q · filed 2022-10-31 | $1.28M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$891.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$1.73M 10-Q · filed 2023-08-07 | $4.81M derived: sum of 3 quarters · filed 2023-08-07 | $5.96M derived: sum of 4 quarters · filed 2023-08-07 | |
| 2022-03-31 | -$838.00K 10-Q · filed 2023-05-15 | $5.70M derived: sum of 2 quarters · filed 2023-05-15 | $6.85M derived: sum of 3 quarters · filed 2023-05-15 | $6.02M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | $6.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $7.69M derived: sum of 2 quarters · filed 2023-03-30 | $6.86M derived: sum of 3 quarters · filed 2023-03-30 | $7.08M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-31 | $318.00K derived: sum of 2 quarters · filed 2022-10-31 | $537.00K 10-Q · filed 2022-10-31 | ||
| 2021-06-30 | -$830.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$611.00K 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $219.00K 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | -$838.00K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |